New drug combo takes on Hard-to-Treat cancers in first human trial

NCT ID NCT06108050

Recruiting now Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing an investigational drug called JZP898, both by itself and together with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the combination can shrink tumors. About 177 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JZP898 (an investigational drug) and pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 177 participants, so the drug may not prove safe or effective. Side effects are unknown, and the combination with pembrolizumab could increase risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Locations

California Cancer Associates for Research and Excellence
RECRUITING

Encinitas, California, 92024, United States
California Cancer Associates for Research and Excellence
RECRUITING

Fresno, California, 93270, United States
Duke University Medical Center - Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Texas Oncology - Baylor Charles A Sammons Cancer Center
RECRUITING

Dallas, Texas, 75246, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.